Introduction
Caroli disease is a rare, congenital condition characterized by segmental dilation of large, intrahepatic bile ducts.[1] Caroli disease belongs to a group of congenital disorders known as fibropolycystic liver diseases, which originate from ductal plate malformations during embryological development and are associated with various liver cysts.[2][3] Caroli disease, also known as congenital communicating cavernous ectasia, was first described in 1958 by Jacques Caroli, a French gastroenterologist, who identified "nonobstructive saccular or fusiform multifocal segmental dilatation of the intrahepatic bile ducts."
In the Todani classification system, type V choledochal cysts refer to "simple Caroli disease," while cystic disease accompanied by congenital hepatic fibrosis is called Caroli syndrome.[4][5][6][7] Simple Caroli disease is usually diagnosed during adolescence and is associated with intermittent abdominal pain, hepatomegaly, and recurrent episodes of cholangitis.[8] Most cases of Caroli disease are sporadic, although it has been rarely associated with autosomal dominant polycystic kidney disease (ADPKD).[9] The diagnosis of Caroli disease is often made using various imaging modalities, with magnetic resonance cholangiopancreatography (MRCP) being the most common.[10]
Caroli syndrome has a higher incidence than Caroli disease, although their clinical presentations are similar. However, Caroli syndrome is also associated with complications arising from hepatic fibrosis and portal hypertension.[5][11] Caroli syndrome commonly coincides with autosomal recessive polycystic kidney disease (ARPKD), as both conditions result from mutations in the same gene (PKHD1).[3][12]
Managing Caroli disease and Caroli syndrome involves addressing complications such as choledocholithiasis and cholangitis, as well as screening for cholangiocarcinoma and hepatocellular carcinoma. For patients with complications related to portal hypertension, early liver transplantation may be considered, as it is the only curative option.[5]
Etiology
Register For Free And Read The Full Article
- Search engine and full access to all medical articles
- 10 free questions in your specialty
- Free CME/CE Activities
- Free daily question in your email
- Save favorite articles to your dashboard
- Emails offering discounts
Learn more about a Subscription to StatPearls Point-of-Care
Etiology
Caroli disease is thought to arise from abnormal embryologic development characterized by ductal plate malformations. The formation of the intrahepatic bile duct system involves the development of the ductal plate, a group of cells that forms around the portal vein branches. During week 12 of gestation, remodeling of the ductal plate leads to the formation of large intrahepatic bile ducts. An arrest in this remodeling process results in Caroli disease.[4]
Ductal plate remodeling is a continuous process of forming bile duct branches in descending size—hepatic, segmental, area, intralobular, and the smallest duct branches. Malformation of the ductal plate can continue to later stages of development, affecting the formation of peripheral or small bile ducts in Caroli syndrome.[13][4] Notably, in contrast to Caroli disease, Caroli syndrome is inherited in an autosomal recessive pattern and commonly occurs concurrently with ARPKD. Both conditions involve mutations in the PKDH1 gene on chromosome 6 (6p12.3-p12.2), and more than 100 mutations have been reported. The PKDH1 gene encodes fibrocystin—a protein primarily expressed in the kidney, with lower expression levels observed in the liver and pancreas.[2][14]
Epidemiology
The estimated prevalence of Caroli disease is approximately 1 case per 1,000,000 people. Caroli syndrome is more common, with an estimated prevalence of 1 in 10,000 to 20,000 live births. Both males and females are equally affected, and the condition is more prevalent among individuals of Asian descent. Over 80% of patients are symptomatic and are subsequently diagnosed before the age of 30.[1][15][5]
Pathophysiology
In Caroli disease, the arrest of the large bile duct during development results in the formation of an intrahepatic cyst. While these cysts affect morphology, liver function is preserved. The cystic dilation of intrahepatic bile ducts may affect a particular liver segment or lobe or involve the entire liver. These malformed bile ducts are significantly dilated and prone to biliary sludge formation and intrahepatic lithiasis, creating a predisposition for infection and recurrent cholangitis. Rarely, recurrent cholangitis and secondary chronic epithelial damage may progress to biliary cirrhosis.[14]
While the exact pathophysiology of Caroli disease is not fully understood, research has highlighted the crucial role of fibrocystin in the development of the cystic dilations and portal fibrosis observed in Caroli syndrome.[16] In the liver, fibrocystin is a component of the cilia on the luminal side of cholangiocytes. Fibrocystin is an important receptor in the protein signaling pathways that regulate bile composition and the apoptotic processes of the biliary epithelium. Cilia detect mechanical, chemical, and osmotic stimuli, which in turn alter bile composition through complex intracellular signaling pathways. Additionally, fibrocystin is involved in the normal development of the liver and kidneys by regulating cell proliferation. A complete absence or significant abnormality of fibrocystin leads to structural damage to the liver parenchyma, resulting in gross cystic dilations and hepatic fibrosis characteristic of Caroli syndrome.[17][18][19][20]
Histopathology
On a microscopic level, Caroli disease is characterized by large bile ducts that are dilated with marked periductal inflammation and soft tissue protrusions into the dilated ducts. These dilations are in communication with the extrahepatic bile ducts. Sometimes, the involvement is confined to a single lobe, with the left lobe being more commonly affected. Histologically, the hepatic cysts demonstrate variable-sized cysts along the portal tract. In congenital hepatic fibrosis (Caroli syndrome), microscopic features include nodularity, extensive septa formation with enlarged portal tracts, and hypoplastic and fibrotic portal vein branches with abnormal branching angles.[2]
History and Physical
Most patients with Caroli disease present with symptoms and are diagnosed before the age of 30. Symptoms arise from abnormal intrahepatic bile ducts, which lead to biliary stasis and sludge formation, causing obstruction of bile flow. The most common presentation includes the classic triad of cholangitis—fever, abdominal pain, and jaundice. Pruritus is also frequently reported due to hyperbilirubinemia from intrahepatic cholestasis. Hepatolithiasis is a common complication of Caroli disease, and in rare cases, stones can obstruct the pancreatic duct.
Although the incidence of pancreatitis in Caroli disease is low, there have been case reports of patients being diagnosed with Caroli disease after presenting with pancreatitis.[15][21] Some patients with Caroli disease may have advanced cystic dilations without a history of cholangitis or liver abscess formation. These patients might present with chronic, intermittent right upper quadrant pain without acute cholangitis.[8]
The presentation of Caroli syndrome can vary, with symptoms appearing either early or later in adolescence. Due to its association with ARPKD, Caroli syndrome may be incidentally diagnosed in neonates presenting with oliguria and respiratory insufficiency.[22] Over time, recurrent cholangitis can lead to biliary cirrhosis and portal hypertension. Individuals aged 30 or older and with Caroli disease, or those with Caroli syndrome, may present with symptoms and signs of portal hypertension, such as splenomegaly, ascites, and variceal bleeding. Additionally, patients with Caroli disease or syndrome are at an increased risk for developing cholangiocarcinoma.[5]
The physical examination of a patient with Caroli disease or syndrome may reveal tenderness in the right upper quadrant, hepatomegaly due to gross enlargement from cystic disease, and splenomegaly due to portal hypertension. As hepatic fibrosis progresses, signs such as shifting dullness and fluid thrill, indicative of ascites, may be observed. Although rare, other signs of cirrhosis, including spider naevi, can also be present.
Evaluation
In Caroli disease, laboratory findings are often nonspecific. In the setting of biliary obstruction or cholangitis, transaminase levels may be elevated, and elevations in serum alkaline phosphatase and direct bilirubin are common.[5] However, unlike other biliary diseases such as primary sclerosing cholangitis, which typically presents with consistently elevated liver-associated enzymes, Caroli disease often has baseline transaminase levels that remain within the normal range.[3][6] Leukocytosis may be observed during cholangitis, while leukopenia and thrombocytopenia may occur if portal hypertension is present.
Various imaging modalities, including ultrasonography, computed tomography (CT), and MRCP, have important roles in evaluating Caroli disease.[2] Ultrasound is typically the initial imaging study due to its cost-effectiveness and limited radiation exposure. Intrahepatic saccular dilations, which may be focal or diffuse, can be visualized on both ultrasound and CT. Additionally, liver fibrosis, varices, and renal cysts can be detected on ultrasound and CT in patients with Caroli syndrome.
In patients with Caroli disease, imaging with contrast-enhanced CT or magnetic resonance imaging (MRI) often reveals the portal triad as a small, enhanced dot within the dilated intrahepatic bile ducts. This imaging finding, known as the "central dot" sign, suggests Caroli disease. While initially considered pathognomonic for Caroli disease, the central dot sign can also be observed in cases of obstructive dilation.[3][23][24]
MRCP is particularly useful for visualizing the entire biliary tract and liver, allowing for the assessment of disease extent and severity.[10] MRCP is also effective in detecting hepatolithiasis and diagnosing cholangiocarcinoma.[10] MRCP is preferred over endoscopic retrograde cholangiopancreatography (ERCP) for evaluation and diagnosis due to the latter's higher risk of precipitating cholangitis and pancreatitis, particularly with the use of contrast dye.[23] Liver biopsy is rarely used in the diagnostic evaluation of Caroli disease or syndrome but may be performed to document associated hepatic fibrosis if necessary.
Treatment / Management
According to the clinical presentation, the mainstay of therapy for patients with Caroli disease is supportive and individualized. Cholangitis resulting from biliary obstruction is treated with antibiotics covering gram-negative and anaerobic rod-shaped bacteria. Adequate biliary drainage may be achieved through biliary stent placement using ERCP or via interventional radiology–guided percutaneous transhepatic catheter (PTC) placement. PTC is generally more effective for draining intrahepatic obstruction, and patients may require indwelling catheters with periodic flushing and changes. Ursodeoxycholic acid is used to manage severe cholestasis and is recommended for patients with Caroli disease or syndrome, even if asymptomatic.[5][25][26][27](A1)
Caroli syndrome is often complicated by portal hypertension, leading to sequelae such as splenomegaly, ascites, and variceal bleeding, which may present during adolescence. These complications should be managed in a traditional manner—endoscopic band ligation for variceal bleeding, nonselective beta blockers for prophylaxis, and diuretics for ascites.[10] Surgical intervention is recommended for patients who remain symptomatic despite conservative management.[6][28] Some authors have recommended segmentectomy, lobectomy, or hepaticojejunostomy, depending on the range of cystic formation, for the treatment of Caroli disease. Studies have shown excellent long-term outcomes with partial hepatectomy or lobectomy in patients with unilobar involvement of Caroli disease.[29][27](B2)
The prevalence of cholangiocarcinoma in Caroli disease and syndrome has been reported as approximately 7%.[30][31] Although general consensus does not exist on screening for cholangiocarcinoma, the European Association for the Study of the Liver guidelines recommend screening with MRCP every 12 months after diagnosis (a weak recommendation with 90% consensus based on available case reports and case-control studies). Monitoring serum tumor markers such as carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA 19-9) is not recommended due to their poor diagnostic accuracy. However, case reports suggest that CA 19-9 may have the potential as a diagnostic marker in asymptomatic patients with polycystic liver disease and ADPKD.[32] (A1)
Liver transplantation is currently the only definitive treatment for Caroli syndrome. Referral for liver transplantation is recommended for patients with Caroli disease or syndrome who are symptomatic with recurrent cholangitis and have either bilobar involvement or monolobar involvement with liver fibrosis or portal hypertension, especially when hepatectomy is not feasible.[33][28][25](A1)
Differential Diagnosis
The differential diagnoses based on clinical presentation include acute cholecystitis, ascending cholangitis, and recurrent pyogenic cholangitis. On imaging, saccular dilations may resemble choledochal cysts seen in autosomal dominant polycystic liver disease, hepatic abscesses, and primary sclerosing cholangitis. MRCP helps distinguish the intrahepatic large duct dilation characteristic of Caroli disease from obstructive bile duct dilation and polycystic liver disease.
Prognosis
The prognosis of Caroli disease varies based on the extent of intrahepatic bile duct dilation and liver involvement. While the condition can often be managed conservatively, individuals with diffuse lobar involvement, recurrent cholangitis, and biliary cirrhosis are at increased risk of morbidity and mortality.
Symptomatic individuals with monolobar involvement generally have good outcomes with partial hepatectomy. However, individuals with multilobar or diffuse liver involvement tend to have poor outcomes with liver resection, making liver transplantation the only definitive treatment.[28][25]
Complications
The most common complication of Caroli disease is recurrent bacterial cholangitis, caused by bile stasis and the formation of intrahepatic calculi. These infections can lead to liver abscesses and sepsis if not promptly treated.[34] Additionally, patients with Caroli disease are at an increased risk of developing cholangiocarcinoma due to chronic inflammation and cellular changes in the bile ducts. Other potential complications include portal hypertension, especially in cases of Caroli syndrome, and hepatic fibrosis, which can progress to cirrhosis and liver failure.
Consultations
Patients with Caroli disease often require a multidisciplinary approach to effectively manage their complex condition. Hepatologists oversee liver health, monitor for complications such as cholangitis, cholangiocarcinoma, and hepatic fibrosis, and coordinate long-term care. Gastroenterologists may be consulted for endoscopic management of bile duct stones and other biliary complications.
Radiologists are critical in accurate diagnosis and ongoing imaging surveillance using modalities such as MRCP. When surgical intervention is necessary, consultation with a transplant surgeon may be required, particularly for patients with advanced liver disease or those being considered for liver transplantation.
Infectious disease specialists may also be involved in treating patients with recurrent bacterial infections. Genetic counseling is recommended for patients and their families, especially when associated with conditions such as polycystic kidney disease, to assess the risk of inheritance and provide guidance on genetic testing.
Deterrence and Patient Education
Deterrence and patient education are crucial in managing Caroli disease. As a definitive cure does not exist, early diagnosis and proactive management are essential to prevent complications. Patients should be informed about the importance of regular imaging studies, maintaining liver health through a balanced diet, and recognizing symptoms of potential infections, such as fever, jaundice, and abdominal pain. Educating patients on seeking prompt medical attention if symptoms arise and understanding the potential benefits of surgical interventions, such as liver resection or transplantation in severe cases, is also important.
Enhancing Healthcare Team Outcomes
Caroli disease is a rare congenital condition characterized by recurrent cholangitis, which can be challenging to differentiate from Caroli syndrome and other fibropolycystic liver diseases. The evaluation, diagnosis, and management of Caroli disease necessitate an interprofessional team of healthcare professionals to ensure early diagnosis and effective management of complications.
With early diagnosis, the healthcare care team can proactively address complications of cholangitis, screen for cholangiocarcinoma, and evaluate patients for liver transplantation early. To enhance patient outcomes, physicians, advanced practitioners, pharmacists, and nurses must collaborate with specialists, including gastroenterologists, hepatologists, nephrologists, radiologists, and transplant surgeons.
Patients can have variable presentations that can manifest during childhood or later in adulthood and require individualized care for effective treatment.[35] Pediatricians and internists should be aware of this condition, as it often necessitates lifelong management. A case manager or care coordinator can facilitate communication between specialists, schedule appointments, and ensure comprehensive care across various settings. This collaborative approach enhances patient outcomes and safety while optimizing team performance by utilizing the expertise of each healthcare professional in managing this complex condition.
References
Desmet VJ. Congenital diseases of intrahepatic bile ducts: variations on the theme "ductal plate malformation". Hepatology (Baltimore, Md.). 1992 Oct:16(4):1069-83 [PubMed PMID: 1398487]
Veigel MC, Prescott-Focht J, Rodriguez MG, Zinati R, Shao L, Moore CA, Lowe LH. Fibropolycystic liver disease in children. Pediatric radiology. 2009 Apr:39(4):317-27; quiz 420-1. doi: 10.1007/s00247-008-1070-z. Epub 2008 Dec 16 [PubMed PMID: 19083218]
Mirza H, Besse W, Somlo S, Weinreb J, Kenney B, Jain D. An update on ductal plate malformations and fibropolycystic diseases of the liver. Human pathology. 2023 Feb:132():102-113. doi: 10.1016/j.humpath.2022.06.022. Epub 2022 Jun 28 [PubMed PMID: 35777701]
Singham J,Yoshida EM,Scudamore CH, Choledochal cysts: part 1 of 3: classification and pathogenesis. Canadian journal of surgery. Journal canadien de chirurgie. 2009 Oct; [PubMed PMID: 19865581]
Yonem O, Bayraktar Y. Clinical characteristics of Caroli's syndrome. World journal of gastroenterology. 2007 Apr 7:13(13):1934-7 [PubMed PMID: 17461493]
Moslim MA, Gunasekaran G, Vogt D, Cruise M, Morris-Stiff G. Surgical Management of Caroli's Disease: Single Center Experience and Review of the Literature. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract. 2015 Nov:19(11):2019-27. doi: 10.1007/s11605-015-2918-9. Epub 2015 Aug 25 [PubMed PMID: 26302876]
Acevedo E, Laínez SS, Cáceres Cano PA, Vivar D. Caroli's Syndrome: An Early Presentation. Cureus. 2020 Oct 18:12(10):e11029. doi: 10.7759/cureus.11029. Epub 2020 Oct 18 [PubMed PMID: 33214957]
Biswas NK, Raju U, Sodhi K. Caroli's Disease. Medical journal, Armed Forces India. 2007 Oct:63(4):388-9. doi: 10.1016/S0377-1237(07)80033-5. Epub 2011 Jul 21 [PubMed PMID: 27408061]
Torra R, Badenas C, Darnell A, Brú C, Escorsell A, Estivill X. Autosomal dominant polycystic kidney disease with anticipation and Caroli's disease associated with a PKD1 mutation. Rapid communication. Kidney international. 1997 Jul:52(1):33-8 [PubMed PMID: 9211343]
Ananthakrishnan AN, Saeian K. Caroli's disease: identification and treatment strategy. Current gastroenterology reports. 2007 Apr:9(2):151-5 [PubMed PMID: 17418061]
Kim JT, Hur YJ, Park JM, Kim MJ, Park YN, Lee JS. Caroli's syndrome with autosomal recessive polycystic kidney disease in a two month old infant. Yonsei medical journal. 2006 Feb 28:47(1):131-4 [PubMed PMID: 16502495]
Bergmann C, Senderek J, Sedlacek B, Pegiazoglou I, Puglia P, Eggermann T, Rudnik-Schöneborn S, Furu L, Onuchic LF, De Baca M, Germino GG, Guay-Woodford L, Somlo S, Moser M, Büttner R, Zerres K. Spectrum of mutations in the gene for autosomal recessive polycystic kidney disease (ARPKD/PKHD1). Journal of the American Society of Nephrology : JASN. 2003 Jan:14(1):76-89 [PubMed PMID: 12506140]
Roskams T, Desmet V. Embryology of extra- and intrahepatic bile ducts, the ductal plate. Anatomical record (Hoboken, N.J. : 2007). 2008 Jun:291(6):628-35. doi: 10.1002/ar.20710. Epub [PubMed PMID: 18484608]
Desmet VJ, Ludwig symposium on biliary disorders--part I. Pathogenesis of ductal plate abnormalities. Mayo Clinic proceedings. 1998 Jan [PubMed PMID: 9443684]
Khan MZ, Kichloo A, El-Amir Z, Shah Zaib M, Wani F. Caroli Disease: A Presentation of Acute Pancreatitis and Cholangitis. Cureus. 2020 Jul 11:12(7):e9135. doi: 10.7759/cureus.9135. Epub 2020 Jul 11 [PubMed PMID: 32789075]
Fabris L, Fiorotto R, Spirli C, Cadamuro M, Mariotti V, Perugorria MJ, Banales JM, Strazzabosco M. Pathobiology of inherited biliary diseases: a roadmap to understand acquired liver diseases. Nature reviews. Gastroenterology & hepatology. 2019 Aug:16(8):497-511. doi: 10.1038/s41575-019-0156-4. Epub [PubMed PMID: 31165788]
Sato Y, Ren XS, Nakanuma Y. Caroli's Disease: Current Knowledge of Its Biliary Pathogenesis Obtained from an Orthologous Rat Model. International journal of hepatology. 2012:2012():107945. doi: 10.1155/2012/107945. Epub 2011 Jul 6 [PubMed PMID: 22007315]
Yang XY, Zhu LP, Liu XQ, Zhang CY, Yao Y, Wu Y. [Genetic diagnosis of Caroli syndrome with autosomal recessive polycystic kidney disease: a case report and literature review]. Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences. 2018 Apr 18:50(2):335-339 [PubMed PMID: 29643536]
Level 3 (low-level) evidenceCabral Correia P, Morgado B. Caroli's Disease as a Cause of Chronic Epigastric Abdominal Pain: Two Case Reports and a Brief Review of the Literature. Cureus. 2017 Sep 20:9(9):e1701. doi: 10.7759/cureus.1701. Epub 2017 Sep 20 [PubMed PMID: 29159008]
Level 3 (low-level) evidenceMamone G, Cortis K, Sarah A, Caruso S, Miraglia R. Hepatic morphology abnormalities: beyond cirrhosis. Abdominal radiology (New York). 2018 Jul:43(7):1612-1626. doi: 10.1007/s00261-017-1351-9. Epub [PubMed PMID: 29043403]
Tsunoda T, Furui J, Yamada M, Eto T, Ura K, Matsumoto T, Segawa T, Motoshima K, Izawa K, Tsuchiya R. Caroli's disease associated with hepatolithiasis: a case report and review of the Japanese literature. Gastroenterologia Japonica. 1991 Feb:26(1):74-9 [PubMed PMID: 2007460]
Level 3 (low-level) evidenceBüscher R, Büscher AK, Weber S, Mohr J, Hegen B, Vester U, Hoyer PF. Clinical manifestations of autosomal recessive polycystic kidney disease (ARPKD): kidney-related and non-kidney-related phenotypes. Pediatric nephrology (Berlin, Germany). 2014 Oct:29(10):1915-25. doi: 10.1007/s00467-013-2634-1. Epub 2013 Oct 10 [PubMed PMID: 24114580]
Singham J, Yoshida EM, Scudamore CH. Choledochal cysts: part 2 of 3: Diagnosis. Canadian journal of surgery. Journal canadien de chirurgie. 2009 Dec:52(6):506-11 [PubMed PMID: 20011188]
Bloustein PA. Association of carcinoma with congenital cystic conditions of the liver and bile ducts. The American journal of gastroenterology. 1977 Jan:67(1):40-6 [PubMed PMID: 851104]
European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of cystic liver diseases. Journal of hepatology. 2022 Oct:77(4):1083-1108. doi: 10.1016/j.jhep.2022.06.002. Epub 2022 Jun 18 [PubMed PMID: 35728731]
Level 1 (high-level) evidenceChen CB, Hu WD, Zhao WW, Gu YY, Hou HW, Pan Z. Laparoscopic hepatectomy for the treatment of Caroli's disease: a case report. Annals of surgical treatment and research. 2018 Mar:94(3):162-165. doi: 10.4174/astr.2018.94.3.162. Epub 2018 Feb 28 [PubMed PMID: 29520352]
Level 3 (low-level) evidenceSingham J, Yoshida EM, Scudamore CH. Choledochal cysts. Part 3 of 3: management. Canadian journal of surgery. Journal canadien de chirurgie. 2010 Feb:53(1):51-6 [PubMed PMID: 20100414]
Bockhorn M, Malagó M, Lang H, Nadalin S, Paul A, Saner F, Frilling A, Broelsch CE. The role of surgery in Caroli's disease. Journal of the American College of Surgeons. 2006 Jun:202(6):928-32 [PubMed PMID: 16735207]
Mabrut JY, Kianmanesh R, Nuzzo G, Castaing D, Boudjema K, Létoublon C, Adham M, Ducerf C, Pruvot FR, Meurisse N, Cherqui D, Azoulay D, Capussotti L, Lerut J, Reding R, Mentha G, Roux A, Gigot JF. Surgical management of congenital intrahepatic bile duct dilatation, Caroli's disease and syndrome: long-term results of the French Association of Surgery Multicenter Study. Annals of surgery. 2013 Nov:258(5):713-21; discussion 721. doi: 10.1097/SLA.0000000000000269. Epub [PubMed PMID: 24121258]
Level 2 (mid-level) evidenceDayton MT, Longmire WP Jr, Tompkins RK. Caroli's Disease: a premalignant condition? American journal of surgery. 1983 Jan:145(1):41-8 [PubMed PMID: 6295196]
Fahrner R, Dennler SG, Inderbitzin D. Risk of malignancy in Caroli disease and syndrome: A systematic review. World journal of gastroenterology. 2020 Aug 21:26(31):4718-4728. doi: 10.3748/wjg.v26.i31.4718. Epub [PubMed PMID: 32884228]
Level 1 (high-level) evidenceKanaan N, Goffin E, Pirson Y, Devuyst O, Hassoun Z. Carbohydrate antigen 19-9 as a diagnostic marker for hepatic cyst infection in autosomal dominant polycystic kidney disease. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2010 May:55(5):916-22. doi: 10.1053/j.ajkd.2009.12.023. Epub 2010 Feb 26 [PubMed PMID: 20189277]
Level 3 (low-level) evidenceLai Q, Lerut J. Proposal for an algorithm for liver transplantation in Caroli's disease and syndrome: putting an uncommon effort into a common task. Clinical transplantation. 2016 Jan:30(1):3-9. doi: 10.1111/ctr.12640. Epub 2015 Oct 19 [PubMed PMID: 26385435]
Issar P, Issar SK. Caroli's disease. Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology. 2014 Sep:33(5):500. doi: 10.1007/s12664-013-0403-5. Epub 2013 Sep 11 [PubMed PMID: 24022473]
Level 3 (low-level) evidenceSun J, Wang S, Chen B. Childhood-onset Caroli's disease as a cause of recurrent fever: A case report. Frontiers in pediatrics. 2022:10():903285. doi: 10.3389/fped.2022.903285. Epub 2022 Aug 4 [PubMed PMID: 35989996]
Level 3 (low-level) evidence